Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Laura McLaughlin, MD
Arkansas Children's Hospital Research Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Children'S Hospital of Colorado
Aurora, Colorado, United States
Chris McKinney, MDNot, yet, recruiting - Children'S Healthcare of Atlanta
Atlanta, Georgia, United States
Elizabeth Stenger, MDRecruiting - Manning Family Children'S
New Orleans, Louisiana, United States
Maria Pereda Ginocchio, MDNot, yet, recruiting - Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Timothy Olson, MD, PhDNot, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 8 Jun 2026
- Primary completion
- 19 Nov 2028
- Completion
- 19 Nov 2029
- Last update posted
- 4 Jun 2026
- Registered enrollment
- 24
- Registry id
- NCT07252050
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.